Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study
EuroIntervention 2016;12:356-358 published online ahead of print June 2015. DOI: 10.4244/EIJY15M06_02
Christoph K. Naber1*, MD; Stylianos A. Pyxaras1, MD; Holger Nef2, MD, PhD; Alexander J. IJsselmuiden3, MD, PhD; Carlo Briguori4, MD, PhD; Christian Schlundt5, MD; Joanna Wykrzykowska6, MD, PhD; Franz R. Eberli7, MD, PhD; Helge Möllmann8, MD, PhD; Søren Galatius9, MD, DMSci; Johannes Rieber10, MD; Philippe Commeau11, MD; Robert-Jan van Geuns12, MD, PhD; David Bouchez1. Contilia Heart and Vascular Center, Elisabeth-Krankenhaus, Essen, Germany; 2. Universitätsklinikum Giessen, Giessen, Germany; 3. Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands; 4. Clinica Mediterranea Hospital, Naples, Italy; 5. Universitätsk
Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxel-eluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice.
